Date Posted
April 14-19, 2023
DCP/PREVENT-Funded Poster Presentations
Poster Session: Late Breaking Poster
April 17, 2023, 9:00 a.m. - 12:30 p.m.
LB114 - Colon cancer preventive efficacy of ONC201 and naproxen alone or in combination in FAP relevant PIRC rat model
Venkateshwar Madka, Gopal Pathuri, Karthikkumar Venkatachalam, Srikanth Chiliveru, Yuting Zhang, Nandini Kumar, Nicole Stratton, Stanley Lightfoot, Mark S. Miller, Shizuko Sei, Chinthalapally V. Rao.
Stephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City, OK, National Cancer Institute, Rockville, MD
https://aacrjournals.org/cancerres/article/83/8_Supplement/LB114/725661
PREVENT Contract 75N91019D00020, Task Order 75N91020F00004
Poster Session: Dietary Derivatives and Repurposed and New Drugs for Cancer Prevention
April 18, 2023, 1:30 p.m. - 5:00 p.m.
5255 - Effect of STAT3 inhibitors, TTI-101 and SH5-07, against bladder cancer in preclinical 3D tumor models
Surya P. Singh1, Gopal Pathuri1, Adam Asch2, Brian Cholewa3, Robert Shoemaker4, Chinthalapally V. Rao1, Venkateshwar Madka1
1Medicine, Center for Cancer Prevention and Drug Development, Stephenson Cancer Center, Hem-Onc Section, University of Oklahoma HSC, Oklahoma City, OK;
2Medicine, Stephenson Cancer Center, Hem-Onc Section, Oklahoma City, OK;
3Division of Cancer Prevention, Chemopreventive Agent Development Research Group, National Cancer Institute, Rockville, MD, OK;
4Division of Cancer Prevention, Chemopreventive Agent Development Research Group, National Cancer Institute, Rockville, MD
https://aacrjournals.org/cancerres/article/83/7_Supplement/5255/721102
PREVENT Contract 75N91019D00020, Task Order 75N91020F00005
5258 - Preclinical testing of CD73 inhibitor AB680 for pancreatic cancer immunoprevention
Lincoln N. Strickland1, Erika Y. Faraoni1, Nicolette R. Mardik1, Lana Vornik2, Michelle I. Savage2, Shizuko Sei3, Mark S. Miller3, Holger K. Eltzschig1, Powel H. Brown2, Florencia McAllister2, Jennifer M. Bailey-Lundberg1
1Anesthesiology, Critical Care and Pain Medicine, University of Texas Health Science Centerz at Houston, Houston, TX;
2Clinical Cancer Prevention, University of Texas MD Anderson Cancer Center, Houston, TX;
3Cancer Prevention, National Cancer Institute, Rockville, MD https://aacrjournals.org/cancerres/article/83/7_Supplement/5258/721099
PREVENT Contract 75N91019D00021, Task Order 75N91020F00002
5260 - Chemopreventive efficacy of everolimus and naproxen combination against carcinogen induced bladder cancer in F344 rats
Venkateshwar Madka1, Gopal Pathuri1, Surya P. Singh1, Anil Singh1, Anh Bao1, Nicole Stratton1, Stanley Lightfoot2, Clinton J. Grubbs3, Jennifer Fox4, John L. Clifford5, Brian Cholewa5, Shizuko Sei5, CV Rao1
1OU Health Stephenson Cancer Center, Oklahoma City, OK;
2formerly VA medical Center, Oklahoma City, OK;
3Formerly University of Alabama, Birmingham, AL;
4National Institute of Aging, NIH, Bethesda, MD;
5Division of Cancer Prevention, NCI, Rockville, MD
https://aacrjournals.org/cancerres/article/83/7_Supplement/5260/721096
PREVENT Contract 75N91019D00020, Task Order 75N91020F00003
Poster Session: Early Detection and Molecular Markers of Prevention
April 19, 2023, 9:00 a.m. - 12:30 p.m.
6518 - Time course genomic characterization reveals progressive accumulation of mutations during tumor development in a Lynch syndrome mouse model
Yurong Song1, Shaneen Baxter1, Lisheng Dai1, Chelsea Sanders1, Holli Loomans-Kropp2, Brandon Somerville1, Ryan N. Baugher1, Stephanie D. Mellott1, Todd B. Young1, Heidi E. Lawhorn1, Teri M. Plona1, Bingfang Xu1, Lei Wei3, Qiang Hu3, Song Liu3, Alan Hutson3, Baktiar Karim1, Simone Difilippantonio1, Ligia Pinto1, Matthias Kloor4, Steven M. Lipkin5, Shizuko Sei6, Robert H. Shoemaker6
1Frederick National Laboratory for Cancer Research, Frederick, MD;
2The Ohio State University, Columbus, OH;
3Roswell Park Comprehensive Cancer Center, Buffalo, NY,:
4University of Heidelberg, Heidelberg, Germany;
5Weill Cornell Medicine, New York, NY;
6Division of Cancer Prevention, Bethesda, MD
https://aacrjournals.org/cancerres/article/83/7_Supplement/6518/722951
PREVENT Contract HHSN261201500039I, Task Order HHSN26100005
DCP/PREVENT Informal Session
Session NIH07 - NCI Funding Opportunities in Cancer Immunoprevention and Chemoprevention
April 16, 2023, 4:00 p.m. - 5:00 p.m.
Presenters
Robert H. Shoemaker, National Cancer Institute, Bethesda, MD
Beyond immunotherapy, towards immunoprevention: NCI journey so far
Altaf Mohammed, National Cancer Institute, Bethesda, MD
Overview of Cancer Immunoprevention Network (CIP-Net)
Sharmistha Ghosh-Janjigian, National Cancer Institute, Bethesda, MD
HTAN pre-Cancer Atlases: Immune targeting opportunities
Mark Steven Miller, National Cancer Institute, Rockville, MD
Overview of PREVENT drug development program
DCP Staff Sessions
Town Meeting
Apr. 17, 2023, 6:00 – 8:00 p.m.
Philip Castle, National Cancer Institute, Rockville, MD
NCI Infrastructure and Programs in Cancer Immunoprevention
Major Symposium
Apr. 18, 2023, 12:30 – 2:00 p.m.
Philip Castle, National Cancer Institute, Rockville, MD
Multi-cancer Early Detection (MCED) Assays: Early Detection Versus Early Distraction